Aclaris Therapeutics, Inc. (ACRS) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -18.15M | -13.13M | -10.93M | -9.99M | -13.06M | -8.94M | 22M | -12.32M | -20.82M | -6.76M | -24.56M | -20.65M |
| Operating CF Margin % | -909.27% | -1013.98% | -331.37% | -562.35% | -897.39% | -97.04% | 506.21% | -445.48% | -868.01% | -38.48% | -264.57% | -1105.08% |
| Operating CF Growth % | -39% | -46.91% | -149.69% | 18.9% | 37.27% | -32.2% | 189.59% | 40.34% | 21.01% | 64.63% | -214.15% | -5.02% |
| Net Income | -19.82M | -19.8M | -14.61M | -15.43M | -15.09M | -96.55M | -7.59M | -10.99M | -16.94M | -1.49M | -29.26M | -29.57M |
| Depreciation & Amortization | 102K | 102K | 210K | 114K | 128K | 143K | 200K | 242K | 243K | 228K | 219K | 218K |
| Stock-Based Compensation | 3.2M | 2.93M | 0 | 3.06M | 3.54M | 2.86M | 0 | 2.9M | 2.09M | 1.27M | 5.95M | 6.52M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.26M | -635K | 0 |
| Other Non-Cash Items | 0 | 400K | 2.86M | 1.5M | 300K | 85.61M | 3.78M | 200K | 2.8M | -26.3M | 2.33M | -1.5M |
| Working Capital Changes | -1.63M | 3.24M | 612K | 759K | -1.94M | -994K | 25.6M | -4.68M | -9.01M | 13.27M | -3.16M | 3.67M |
| Change in Receivables | 742K | 0 | 6.69M | 56K | 68K | 25K | -18K | 48K | -75K | 48K | 85K | 255K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.51M | 3.96M | 377K | 2.44M | 1.66M | -2.97M | 393K | -3.54M | 1.93M | -394K | -2.15M | 3.23M |
| Cash from Investing | -30.93M | 10.37M | 13.83M | 5.05M | 19.12M | -88.72M | 2.79M | -674K | 16.83M | 7.55M | 32.53M | -19.66M |
| Capital Expenditures | -13K | -24K | -23K | -21K | -43K | -35.81M | 0 | 14K | -135K | -441K | -84K | -231K |
| CapEx % of Revenue | 0.65% | 1.85% | 0.7% | 1.18% | 2.96% | 388.77% | - | 0.51% | 5.63% | 2.51% | 0.91% | 12.36% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -32.62M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -833K | 0 | 0 | 0 | 0 | 0 | 32.62M | 0 |
| Cash from Financing | 57.78M | -2.53M | -3.04M | -9K | -275K | 74.58M | 22K | -11K | -55K | 49K | -87K | 26.74M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 58.03M | 0 | 0 | -9K | -275K | 74.91M | 32K | -11K | -55K | 49K | 15K | 26.74M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -9K | -275K | 0 | 0 | -11K | -55K | 0 | 0 | 0 |
| Other Financing | -250K | -2.53M | -3.04M | 0 | 0 | -333K | -10K | 0 | 0 | 0 | -102K | 0 |
| Net Change in Cash | 8.7M | -5.3M | -146K | -4.96M | 5.79M | -23.08M | 24.82M | -13.01M | -4.04M | 838K | 7.89M | -13.57M |
| Free Cash Flow | -18.15M | -13.15M | -10.96M | -10.01M | -13.1M | -44.75M | 22M | -12.31M | -20.95M | -7.2M | -24.64M | -20.89M |
| FCF Margin % | -909.27% | -1015.83% | -332.07% | -563.53% | -900.34% | -485.81% | 506.21% | -444.97% | -873.64% | -40.99% | -265.47% | -1117.44% |
| FCF Growth % | -38.54% | 70.6% | -149.8% | 18.64% | 37.47% | -521.33% | 189.28% | 41.07% | 22.14% | 62.53% | -209.29% | -5.2% |
| FCF per Share | -0.14 | -0.11 | -0.09 | -0.08 | -0.11 | -0.47 | 0.31 | -0.17 | -0.29 | -0.10 | -0.35 | -0.30 |
| FCF Conversion (FCF/Net Income) | 0.92x | 0.66x | 0.75x | 0.65x | 0.87x | 0.09x | -2.90x | 1.12x | 1.23x | 4.53x | 0.84x | 0.70x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |